SS
Therapeutic Areas
ConSynance Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CSTI-500 | Prader-Willi Syndrome (Hyperphagia & Neurobehavioral Challenges) | Phase 2 |
| CSTI-100 / HBS-102 | Rare Neurological Disorders | Preclinical |
Leadership Team at ConSynance Therapeutics
SL
Shuang Liu, PhD
Founder & CEO
JR
Jill Rasmussen, MD
Acting Medical Director
JM
John Maki
Strategic Advisor